计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T414072-1mg |
1mg |
现货 ![]() |
| |
| T414072-5mg |
5mg |
现货 ![]() |
| |
| T414072-10mg |
10mg |
现货 ![]() |
| |
| T414072-25mg |
25mg |
现货 ![]() |
| |
| T414072-50mg |
50mg |
现货 ![]() |
| |
| T414072-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | SCHEMBL247509 | AC-35865 | s8584 | AKOS032946520 | XILIERTINIB [WHO-DD] | 6ZZ3B7NZ0B | Pyrrolo(3,4-b)pyrrole-5(1H)-carboxamide, N-(4-((3-ethynylphenyl)amino)-7-methoxy-6-quinazolinyl)hexahydro-1-methyl-, (3aR,6aR)- | (3aR,6aR)-N-[4-(3-ethynylanilino)-7-me |
|---|---|
| 规格或纯度 | Moligand™, ≥96% |
| 英文名称 | Theliatinib (HMPL-309) |
| 生化机理 | Theliatinib (HMPL-309) 是一种高效的表皮生长因子受体抑制剂,对野生型表皮生长因子受体的 Ki 值为 0.05 nM,对表皮生长因子受体和表皮生长因子受体 T790M/L858R 突变体的 IC50 值分别为 3 nM 和 22 nM。与其他 72 种激酶相比,它对表皮生长因子受体的选择性高出 50 倍。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 表皮生长因子受体抑制剂;erb-b2 受体酪氨酸激酶 4 抑制剂;LCK 原癌基因抑制剂;Src 家族酪氨酸激酶;LYN 原癌基因抑制剂;Src 家族酪氨酸激酶;酪氨酸激酶非受体 1 抑制剂;YES 原癌基因 1 抑制剂;Src 家族酪氨酸激酶 |
| 产品介绍 |
Theliatinib 是一种ATP 竞争性高度选择性的EGFR 抑制剂,Ki 为 0.05 nM,IC50为 3 nM。它具有抗肿瘤活性,对EGFR T790M/L858R 突变体的IC50值为 22 nM。它对EGFR 的选择性是其他激酶的 50 倍以上。
Targets WT EGFR (Cell-free assay); EGFR T790M/L858R (Cell-free assay) 3 nM; 22 nM In vitro In comparison to erlotinib or gefitnib, theliatinib shows much stronger binding affinity to wild type EGFR and is more difficult to be replaced by ATP. This unique feature may result in better target engagement for theliatinib compared to erlotinib or gefitinib, leading to stronger anti-tumor activity in tumors with wild type EGFR activation due to gene amplification or protein overexpression. Theliatinib inhibits EGFR phosphorylation with an IC50 of 0.007 μM for EGF stimulated EGFR phosphorylation in A431 cells and cell survival in tumor cells with wild-type EGFR (A431, H292, FaDu cells). Theliatinib demonstrates dose-dependent anti-tumor activity in a panel of PDECX (patient-derived esophageal cancer xenograft) models with a generally good correlation between EGFR H score and tumor growth inhibition. Furthermore, aberrant activation or gene mutations of other targets such as PI3K and FGFR diminishes the anti-tumor activity of the EGFR TKIs, especially, theliatinib. Cell Research(from reference) Cell lines:A431 cells Concentrations:0.005-10 μM Incubation Time:48 h |
| 纯度 | ≥96% |
| IC50 | WT EGFR, IC50: 3 nM |
|---|
| IIUPAC Name | (3aR,6aR)-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]-1-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxamide |
|---|---|
| INCHI | 1S/C25H26N6O2/c1-4-16-6-5-7-18(10-16)28-24-19-11-21(23(33-3)12-20(19)26-15-27-24)29-25(32)31-13-17-8-9-30(2)22(17)14-31/h1,5-7,10-12,15,17,22H,8-9,13-14H2,2-3H3,(H,29,32)(H,26,27,28)/t17-,22+/m1/s1 |
| InChi Key | FSXCKIBROURMFT-VGSWGCGISA-N |
| Smiles | CN1CCC2C1CN(C2)C(=O)NC3=C(C=C4C(=C3)C(=NC=N4)NC5=CC=CC(=C5)C#C)OC |
| Isomeric SMILES | CN1CC[C@H]2[C@@H]1CN(C2)C(=O)NC3=C(C=C4C(=C3)C(=NC=N4)NC5=CC=CC(=C5)C#C)OC |
| PubChem CID | 54759275 |
| 分子量 | 442.51 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 47 mg/mL (106.21 mM); |
|---|---|
| 分子量 | 442.500 g/mol |
| XLogP3 | 3.100 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 442.212 Da |
| 单同位素质量Monoisotopic Mass | 442.212 Da |
| 拓扑极表面积Topological Polar Surface Area | 82.600 Ų |
| 重原子数Heavy Atom Count | 33 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 754.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Ren Y, Zheng J, Fan S, Wang L, Cheng M, Shi D, Zhang W, Tang R, Yu Y, Jiao L et al.. (2017) Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.. Oncotarget, 8 (31): (50832-50844). [PMID:28881608] |